Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGN-EDODM1 in Myotonic Dystrophy Type 1
NCT06667453Phase 2Recruiting
- Sponsor
- PepGen
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing PGN-EDODM1 with Placebo (2 arms). Primary endpoint: Adverse Events at 112 days. Started Dec 2024; status: recruiting.
02
Drugs
PGN-EDODM1
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06667453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667453.